NEW YORK, June 25, 2020 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced the public filing of a

NEW YORK, June 12, 2020 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announced that it has received a

NEW YORK, May 18, 2020 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has

NEW YORK, April 27, 2020 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announced  today  that it has received ISO 13485:2016 certification for its development and commercial laboratory

NEW YORK, April 20, 2020 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence  in vitro  diagnostics for kidney disease, announces  that the  KidneyIntelX™  platform will be used by investigators from the Icahn School of Medicine

Oral presentation accepted for Late Breaking session of the National Kidney Foundation Spring Clinical Meeting Accompanying abstract accepted for publication in American Journal of Kidney Disease   NEW YORK, March 24, 2020 /PRNewswire/ --  Renalytix AI plc (LSE: RENX),  the AIM-traded developer of

NEW YORK, March 2, 2020 /PRNewswire/ --  Renalytix AI plc  (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces it will be presenting at the  Cowen 40th Annual Health Care Conference  taking place on March 1-4, 2020, at the Boston Marriott

NEW YORK, Dec. 3, 2019 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the Centers for Medicare and Medicaid Services ("CMS") has released the Final 2020 Clinical Laboratory Fee Schedule

Effective October 16, KidneyIntelX will be covered for reimbursement for qualified members NEW YORK, Oct. 17, 2019 /PRNewswire/ --  Renalytix AI plc  (AIM: RENX), a developer of artificial intelligence enabled clinical diagnostics for kidney disease, announces that Capital District Physicians'

NEW YORK, Oct. 14, 2019 /PRNewswire/ --  Renalytix AI plc  (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today the appointment of leading kidney investigator and clinician Dr. Chirag Parikh to the Renalytix board. Dr.